TL;DR: The Centers for Medicare & Medicaid Services modified NCD 102, its lipid testing coverage policy, with an effective date of March 7, 2026. Here's what billing teams need to know to protect reimbursement and avoid claim denial.
This update touches one of the most common diagnostic lab services billed under Medicare. NCD 102 in the CMS system governs when Medicare covers lipid panels and individual lipid components — total cholesterol, LDL-C, HDL-C, and triglycerides — for cardiovascular risk assessment and ongoing therapy monitoring. The policy does not list specific CPT or HCPCS codes in this version, so your team needs to map coverage criteria to your existing charge capture. If you're not sure how this applies to your patient mix, loop in your compliance officer before billing under the updated policy.
Quick-Reference Table
| Field | Detail |
|---|---|
| Payer | CMS (Centers for Medicare & Medicaid Services) |
| Policy | Lipid Testing |
| Policy Code | NCD 102 |
| Change Type | Modified |
| Effective Date | 2026-03-07 |
| Impact Level | High — broad patient population, high claim volume |
| Specialties Affected | Cardiology, primary care, endocrinology, nephrology, internal medicine |
| Key Action | Audit your lipid testing frequency documentation against the updated NCD 102 criteria before March 7, 2026 |
CMS Lipid Testing Coverage Criteria and Medical Necessity Requirements 2026
NCD 102 is the National Coverage Determination governing whether Medicare covers lipid testing for a given patient. The CMS lipid testing coverage policy draws a clear line: coverage depends on documented medical necessity, tied to specific clinical indications and frequency limits. Get either of those wrong and you're looking at a claim denial.
The policy recognizes lipid testing as appropriate for evaluating atherosclerotic cardiovascular disease. That's the anchor. Every covered indication flows from that clinical framework.
Covered Clinical Indications
Medicare covers lipid testing under NCD 102 when the patient presents with one of these documented conditions or scenarios:
| # | Covered Indication |
|---|---|
| 1 | Assessment of atherosclerotic cardiovascular disease — any form of atherosclerotic disease, or any disease that leads to its formation |
| 2 | Primary dyslipidemia evaluation — when the patient has a known or suspected dyslipidemia not caused by another condition |
| 3 | Diseases associated with altered lipid metabolism — this includes nephrotic syndrome, pancreatitis, hepatic disease, hypothyroidism, and hyperthyroidism |
| 4 | Secondary dyslipidemia — diabetes mellitus, disorders of gastrointestinal absorption, and chronic renal failure all qualify |
| 5 | Signs or symptoms of dyslipidemia — skin lesions (xanthomas, for example) are the classic example the policy names |
| 6 | Follow-up to an initial coronary heart disease screen — specifically when total cholesterol exceeds 240 mg/dL, or when total cholesterol is borderline-high (200–240 mg/dL) plus two or more coronary heart disease risk factors, or when HDL cholesterol falls below 35 mg/dL |
That last bullet is worth reading twice. The total cholesterol threshold is a hard number in the policy: 240 mg/dL. If you're billing follow-up lipid testing after an initial screen, your documentation needs to show the patient hit that threshold — or the borderline-high plus risk factor combination. A claim without that documented trigger is vulnerable.
Monitoring: Frequency Is Where Claims Break Down
The medical necessity rules for monitoring are more granular than the initial evaluation rules. This is where lipid testing billing gets complicated.
For patients on anti-lipid dietary management or pharmacologic therapy, total cholesterol, HDL-C, and LDL-C may be used to monitor progress. Triglycerides come into play when that fraction is also elevated — or when the patient starts a drug known to raise triglyceride levels. The policy names specific drug classes: thiazide diuretics, beta blockers, estrogens, glucocorticoids, and tamoxifen. If your patient is on any of those, triglyceride monitoring has a clear medical necessity basis. Document the medication.
For long-term monitoring of anti-lipid therapy, the policy considers annual lipid panels generally adequate. Between annual panels, a serum total cholesterol or measured LDL alone should suffice — unless the patient has hypertriglyceridemia.
Here's the frequency ceiling that matters most for high-volume billers: any single component of the lipid panel, or a measured LDL, is reasonable and necessary up to six times in the first year when monitoring dietary or pharmacologic therapy. After that first year, annual is the standard. More frequent testing requires documented clinical justification. Without it, expect a denial.
Prior Authorization
NCD 102 does not explicitly require prior authorization for lipid testing. But that doesn't mean you're in the clear. Local Coverage Determinations from your Medicare Administrative Contractor may layer additional prior auth or documentation requirements on top of the NCD. Check with your MAC before assuming national policy is the only policy that applies.
CMS Lipid Testing Exclusions and Non-Covered Indications
The policy doesn't frame exclusions as a separate list, but the frequency limits function as a practical exclusion. Testing that exceeds the stated frequency thresholds without documented clinical justification is not covered. That's the real exposure here.
Testing performed purely as a routine screen — with no documented cardiovascular risk factors, dyslipidemia, or relevant comorbidity — falls outside the covered indications. Medicare is not paying for lipid panels that aren't tied to a covered clinical reason. Your diagnosis coding has to match the indication, not just reference a generic "screening" visit.
More frequent testing than the policy allows is the single biggest claim denial risk under this coverage policy. A patient getting lipid panels every month during a stable period of anti-lipid therapy doesn't have a covered claim unless the chart supports medical necessity for that frequency.
Coverage Indications at a Glance
| Indication | Status | Relevant Codes | Notes |
|---|---|---|---|
| Atherosclerotic cardiovascular disease assessment | Covered | No specific codes listed in NCD 102 | Documentation of disease required |
| Primary dyslipidemia evaluation | Covered | No specific codes listed in NCD 102 | Document dyslipidemia type |
| Secondary dyslipidemia (diabetes, CRF, GI absorption disorders) | Covered | No specific codes listed in NCD 102 | Document underlying condition |
| Diseases with altered lipid metabolism (nephrotic syndrome, pancreatitis, hepatic disease, thyroid disorders) | Covered | No specific codes listed in NCD 102 | Comorbidity must be documented |
| Signs/symptoms of dyslipidemia (e.g., skin lesions) | Covered | No specific codes listed in NCD 102 | Clinical findings must appear in chart |
| Follow-up after initial CHD screen (total cholesterol >240 mg/dL) | Covered | No specific codes listed in NCD 102 | Threshold must be documented |
| Follow-up after initial CHD screen (borderline-high + 2+ risk factors, or HDL <35 mg/dL) | Covered | No specific codes listed in NCD 102 | Both conditions must be documented |
| Monitoring on anti-lipid therapy — first year (up to 6x per component) | Covered | No specific codes listed in NCD 102 | Frequency limit is strict; document each visit need |
| Long-term monitoring on stable anti-lipid therapy | Covered (annual) | No specific codes listed in NCD 102 | Annual lipid panel standard; interim visits may use total cholesterol or LDL only |
| Triglyceride monitoring on triglyceride-raising medications | Covered | No specific codes listed in NCD 102 | Document specific drug (thiazide, beta blocker, estrogen, glucocorticoid, tamoxifen) |
| Routine screening without documented indication | Not Covered | N/A | No cardiovascular risk or clinical basis = denial risk |
| Testing exceeding frequency limits without documented justification | Not Covered | N/A | Chart must support deviation from standard intervals |
CMS Lipid Testing Billing Guidelines and Action Items 2026
| # | Action Item |
|---|---|
| 1 | Audit your diagnosis coding before March 7, 2026. Every lipid testing claim needs an ICD-10-CM code that maps to a covered indication under NCD 102. Pull a sample of recent lipid testing claims and verify each one has a diagnosis that matches the policy's covered indications — atherosclerotic disease, dyslipidemia, relevant comorbidities, or a documented threshold result from a prior screen. |
| 2 | Build frequency tracking into your charge capture workflow. The policy allows up to six lipid component tests in the first year of monitoring anti-lipid therapy. After year one, annual is the standard. If your EHR or billing system doesn't flag when a patient approaches that frequency ceiling, claims will slip through without supporting documentation — and Medicare will deny them on audit. |
| 3 | Document the clinical trigger for every follow-up test. "Lipid panel ordered" is not enough. The chart needs to show why — stable therapy check, medication change, new triglyceride-raising drug, new symptom, or a documented lab value that hit a threshold. This is where lipid testing billing fails most often. The test is routine. The documentation is not. |
| 4 | Check your MAC's local coverage determination. NCD 102 sets the national floor for CMS lipid testing coverage policy. Your Medicare Administrative Contractor may have an LCD that adds documentation requirements, expands covered diagnoses, or restricts frequency further. Contact your MAC or check their website for any applicable LCD before the effective date. |
| 5 | Review orders for triglyceride testing separately. Triglycerides are not automatically included in every lipid monitoring scenario. Under NCD 102, triglyceride testing is covered when that fraction is elevated or when the patient is on a drug known to raise triglyceride levels. Verify your providers are documenting one of those two conditions when they order triglycerides alongside a lipid panel. Standalone triglyceride orders without that documentation are a denial waiting to happen. |
| 6 | Flag interim visits for correct component selection. The policy is clear that between annual full lipid panels, a serum total cholesterol or measured LDL alone is sufficient for stable patients without hypertriglyceridemia. Billing a full lipid panel at every interim visit — when the clinical situation doesn't require it — overstates medical necessity and creates audit exposure. Your providers may not realize the policy draws this distinction. Brief them before March 7, 2026. |
| Previous Version | Current Version |
|---|---|
| Coverage is considered experimental and investigational for all indications | Coverage is considered medically necessary when specific criteria are met |
| Prior authorization is not required | Prior authorization is required for initial treatment |
| Documentation must include clinical history | Documentation must include clinical history |
| Re-review every 24 months | Re-review every 12 months with updated clinical documentation |
CPT, HCPCS, and ICD-10 Codes for Lipid Testing Under NCD 102
A Note on Codes
NCD 102 (policy key 102-v2), as modified effective March 7, 2026, does not list specific CPT, HCPCS, or ICD-10 codes in the policy document. This is a coverage determination that defines clinical indications and frequency criteria — not a code-level billing grid.
Your billing team should map the covered indications to the appropriate CPT codes for lipid testing (including individual components and panel codes) and pair them with the ICD-10-CM codes that document the clinical indication. If you're unsure which codes your MAC recognizes as covered under NCD 102, pull your MAC's published billing guidelines or contact their provider outreach line directly.
Do not assume that because a CPT code exists for a lipid test, it's automatically covered. Coverage under NCD 102 is indication-driven and frequency-limited. The code is only as good as the documentation behind it. If your team needs help mapping codes to NCD 102 criteria, talk to your billing consultant or compliance officer before the March 7, 2026 effective date.
Get the Full Picture
Track this policy across versions, search 1,500+ policies by CPT code, and get real-time alerts when any payer changes coverage.